Concert Pharmaceuticals (NASDAQ:CNCE) issued its earnings results on Thursday. The biotechnology company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.13, Fidelity Earnings reports. Concert Pharmaceuticals had a negative net margin of 7,303.34% and a negative return on equity of 49.44%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.35 million.
Shares of NASDAQ CNCE traded up $0.33 on Friday, hitting $6.73. The company’s stock had a trading volume of 303,600 shares, compared to its average volume of 223,753. Concert Pharmaceuticals has a 12-month low of $5.36 and a 12-month high of $17.83. The stock has a 50 day moving average of $6.77 and a 200-day moving average of $9.76. The company has a market capitalization of $152.32 million, a price-to-earnings ratio of -2.80 and a beta of 0.88. The company has a debt-to-equity ratio of 0.12, a current ratio of 19.63 and a quick ratio of 19.63.
Several research analysts have weighed in on the stock. HC Wainwright lowered their target price on shares of Concert Pharmaceuticals from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, October 3rd. Stifel Nicolaus lowered shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the stock from $18.00 to $8.00 in a research report on Friday, September 27th. Zacks Investment Research lowered shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday. Mizuho restated a “buy” rating and set a $18.00 target price on shares of Concert Pharmaceuticals in a research report on Friday. Finally, SunTrust Banks lowered their target price on shares of Concert Pharmaceuticals from $30.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, September 30th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. Concert Pharmaceuticals currently has an average rating of “Hold” and an average price target of $15.63.
In other Concert Pharmaceuticals news, Director Heek Christi Van acquired 5,000 shares of the company’s stock in a transaction dated Tuesday, October 8th. The stock was bought at an average price of $5.90 per share, with a total value of $29,500.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $29,500. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 11.00% of the stock is owned by corporate insiders.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Further Reading: Should you buy a closed-end mutual fund?
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.